Perspectives on Combination Immunotherapy in NSCLC
Many immunotherapy-based combinations are being studied in NSCLC, with TMB emerging as a potential predictive biomarker.
Diagnosis & Disease Information
Tislelizumab Shows Antitumor Activity in Lung Cancer
Tislelizumab, an anti-PD-1 antibody, demonstrated antitumor activity in phase 1 and phase 2 trials of Chinese patients with advanced lung cancers.
CT Screening Reduces Lung Cancer Deaths in High-Risk Asymptomatic Patients
CT lung cancer screening substantially reduces lung cancer deaths among asymptomatic patients at high risk for developing lung cancer.
A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
Humans are used to seeing canines used as tools in forensics — their skills are often harnessed to smell out drugs or trail a criminal. Some dogs are even used to locate household pests. The use of canines to detect lung cancer from smell alone, however, is a new prospect for oncologists and their patients.
Future Perspectives for Targeted Therapy in NSCLC
New approaches are needed in the future to further improve outcomes with targeted therapy in NSCLC.
Pathologic Tumor Analysis Leads Progress in the Understanding and Treatment of NSCLC
Pathologic analysis of tumor tissue has led to the improved understanding of the molecular drivers of NSCLC.
MET Inhibitor Shows Antitumor Activity in Advanced NSCLC
Interim data from a phase 2 trial suggests that MET inhibitor tepotinib has antitumor activity and a tolerable safety profile in advanced MET exon 14 skipping mutated NSCLC.
First-Line Osimertinib Effective Regardless of PD-L1 Expression in EGFR-Mutated NSCLC
An analysis of the phase 3 FLAURA trial demonstrated that osimertinib efficacy was not affected by PD-L1 tumor expression.
irAEs Associated With Prolonged PFS and OS in NSCLC
A retrospective study suggested that irAEs with second-line nivolumab are associated with PFS and OS in patients with advanced NSCLC.
Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
Despite promising prior data on nintedanib, the addition of the drug to a standard regimen did not improve survival in patients with a specific type of lung cancer.
- Loading...
Loading...
Next post in IASLC 2018
Loading... 
Loading...